In addition, the acquisition of Blueprint brings Sanofi an established presence among allergists, dermatologists, and immunologists, which is expected to enhance Sanofi’s ability to advance its growing immunology pipeline.
The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and EU. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM).
The accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract and other organs characterise this.
The acquisition also includes elenestinib, a next-generation medicine for SM that is a potent and highly selective KIT D816V inhibitor with limited central nervous system penetration.
The oral investigational ISM medication is the subject of HARBOR, a Phase 2/3 study (Clinical Study Identifier: NCT04910685).
The ongoing, randomised, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of elenestinib plus symptom-directed therapy in patients with ISM and smouldering SM.
Sanofi also acquired BLU-808, an investigational oral, highly potent and selective wild-type KIT inhibitor. Wild-type KIT plays a central role in mast cell activation, which is implicated in a broad range of inflammatory diseases.
Sanofi is financing the transaction with a combination of cash on hand and proceeds from commercial paper issuances; the acquisition will not have a significant impact on Sanofi’s financial guidance for 2025.
It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026.
